Catalist-listed iX Biopharma has announced that its novel Wafermine sublingual ketamine wafers will be used in a study to evaluate its use as a treatment for pain suffered by patients with advanced cancer.

The pilot study will be funded by Chris O’Brien Lifehouse, a comprehensive cancer hospital in Camperdown, Sydney.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply


Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook